BioSpace News Archive

RevBio, Inc., announced that it has been awarded a grant from the National Institute on Aging (NIA), part of the National Institutes of Health (NIH), through its Commercialization Readiness Program of up to $3.4 million over the next three years (1SB1AG085803-01).

Atara Biotherapeutics, Inc. reported the grant of 56,750 restricted stock units of Atara’s common stock to four newly hired employees.

Assertio Holdings, Inc., a specialty pharmaceutical company offering differentiated products to patients, announced that effective October 4, 2023, the Compensation Committee of the Company’s Board of Directors granted one newly-hired employee a total of 9,800 restricted stock units and 11,575 stock options.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2023 financial results on Wednesday, November 8, 2023, at 7:00 a.m. ET.

Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our) today announced the acceptance of abstracts on the bispecific antibody MCLA-129 in non-small cell lung cancer (NSCLC) and in previously treated head and neck squamous cell carcinoma (HNSCC) for presentation at the European Society for Medical Oncology Congress (ESMO) Asia Congress 2023 taking place in Singapore December 1-3, 2023.

enVVeno Medical Corporation (Nasdaq:NVNO) (“enVVeno” or the “Company”), a company setting new standards of care for the treatment of venous disease, today announced that it has achieved full enrollment in SAVVE®️, the 75 person U.S. pivotal trial for the VenoValve®️ and the final precursor for seeking FDA pre-market approval of the VenoValve.

PN Medical, a cardiopulmonary device manufacturer developing combined respiratory muscle training (cRMT) devices, today announced that it has initiated a study to evaluate its flagship device

Talaris Therapeutics, Inc. announced that its Board of Directors has declared a special dividend in connection with the previously announced merger with Tourmaline Bio, Inc. pursuant to the Agreement and Plan of Merger, dated June 22, 2023.

Olympus Corporation (Olympus), a global MedTech company committed to making people’s lives healthier, safer and more fulfilling, named Dr. John de Csepel to the role of Chief Medical Officer (CMO), effective immediately.

Sensient Technologies Corporation will hold its conference call to discuss 2023 third quarter results at 8:30 a.m. CDT on Friday, October 20, 2023.